CME/CE

Faculty: Komal Jhaveri, MD, FACP Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly red...

Faculty: Komal Jhaveri, MD, FACP Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly red...

Faculty: Komal Jhaveri, MD, FACP Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly red...

Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoti...

Host: An De Vriese, MD, PhD Faculty: Muh Geot Wong, MBBS, PhD Join Drs. An de Vriese and Muh Geot Wong in a case-based discussion on optimizing long-term kidney outcomes in patients with IgA nephropathy (IgAN). Faculty review the new KDIGO guidelines, including more aggressive treatment targets such as proteinuria levels below 0.3 g/day. A clinical case is used to illustrate practical guideline ap...

Host: An De Vriese, MD, PhD Faculty: Muh Geot Wong, MBBS, PhD Join Drs. An de Vriese and Muh Geot Wong in a case-based discussion on optimizing long-term kidney outcomes in patients with IgA nephropathy (IgAN). Faculty review the new KDIGO guidelines, including more aggressive treatment targets such as proteinuria levels below 0.3 g/day. A clinical case is used to illustrate practical guideline ap...

Faculty: John McMurray, MD Faculty: Scott Solomon, MD Join Drs. Scott Solomon and John McMurray as they examine the new indication for finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in treating patients with heart failure with LVEF ≥40%. Drawing on data from the FINEARTS-HF trial, faculty discuss patient selection, dosing considerations based on renal function, and the additive...

Faculty: James M. Cleary, MD, PhD This activity examines first-line treatment strategies for advanced HER2-negative upper gastrointestinal cancers. Expert commentary highlights the role of biomarker testing, including PD-L1 CPS and CLDN18.2, in guiding therapeutic decisions. Key clinical trial data on anti-PD-1 therapies such as nivolumab, pembrolizumab, and tislelizumab are discussed, along with...

Faculty: James M. Cleary, MD, PhD This activity examines first-line treatment strategies for advanced HER2-negative upper gastrointestinal cancers. Expert commentary highlights the role of biomarker testing, including PD-L1 CPS and CLDN18.2, in guiding therapeutic decisions. Key clinical trial data on anti-PD-1 therapies such as nivolumab, pembrolizumab, and tislelizumab are discussed, along with...

Faculty: James M. Cleary, MD, PhD This activity examines first-line treatment strategies for advanced HER2-negative upper gastrointestinal cancers. Expert commentary highlights the role of biomarker testing, including PD-L1 CPS and CLDN18.2, in guiding therapeutic decisions. Key clinical trial data on anti-PD-1 therapies such as nivolumab, pembrolizumab, and tislelizumab are discussed, along with...

Faculty: James M. Cleary, MD, PhD This activity examines first-line treatment strategies for advanced HER2-negative upper gastrointestinal cancers. Expert commentary highlights the role of biomarker testing, including PD-L1 CPS and CLDN18.2, in guiding therapeutic decisions. Key clinical trial data on anti-PD-1 therapies such as nivolumab, pembrolizumab, and tislelizumab are discussed, along with...

Faculty: Luis Paz-Ares, MD, PhD Faculty: Lauren A. Byers, MD This online CME program will provide the latest clinical updates on B7-H3–directed antibody-drug conjugates (ADCs) in extensive-stage small cell lung cancer (ES-SCLC). Faculty experts will review the biological rationale for targeting B7-H3 in ES-SCLC and discuss recent clinical evidence on B7-H3 ADCs presented at WCLC and ESMO 2025. Par...

Faculty: Luis Paz-Ares, MD, PhD Faculty: Lauren A. Byers, MD This online CME program will provide the latest clinical updates on B7-H3–directed antibody-drug conjugates (ADCs) in extensive-stage small cell lung cancer (ES-SCLC). Faculty experts will review the biological rationale for targeting B7-H3 in ES-SCLC and discuss recent clinical evidence on B7-H3 ADCs presented at WCLC and ESMO 2025. Par...

Faculty: Luis Paz-Ares, MD, PhD This online CME program will provide the latest clinical updates on B7-H3–directed antibody-drug conjugates (ADCs) in extensive-stage small cell lung cancer (ES-SCLC). Faculty experts will review the biological rationale for targeting B7-H3 in ES-SCLC and discuss recent clinical evidence on B7-H3 ADCs presented at WCLC and ESMO 2025. Participants will gain practical...

Faculty: Luis Paz-Ares, MD, PhD Faculty: Lauren A. Byers, MD This online CME program will provide the latest clinical updates on B7-H3–directed antibody-drug conjugates (ADCs) in extensive-stage small cell lung cancer (ES-SCLC). Faculty experts will review the biological rationale for targeting B7-H3 in ES-SCLC and discuss recent clinical evidence on B7-H3 ADCs presented at WCLC and ESMO 2025. Par...

Faculty: Luis Paz-Ares, MD, PhD Faculty: Lauren A. Byers, MD This online CME program will provide the latest clinical updates on B7-H3–directed antibody-drug conjugates (ADCs) in extensive-stage small cell lung cancer (ES-SCLC). Faculty experts will review the biological rationale for targeting B7-H3 in ES-SCLC and discuss recent clinical evidence on B7-H3 ADCs presented at WCLC and ESMO 2025. Par...

Faculty: Lauren A. Byers, MD This online CME program will provide the latest clinical updates on B7-H3–directed antibody-drug conjugates (ADCs) in extensive-stage small cell lung cancer (ES-SCLC). Faculty experts will review the biological rationale for targeting B7-H3 in ES-SCLC and discuss recent clinical evidence on B7-H3 ADCs presented at WCLC and ESMO 2025. Participants will gain practical in...

Faculty: Luis Paz-Ares, MD, PhD Faculty: Lauren A. Byers, MD This online CME program will provide the latest clinical updates on B7-H3–directed antibody-drug conjugates (ADCs) in extensive-stage small cell lung cancer (ES-SCLC). Faculty experts will review the biological rationale for targeting B7-H3 in ES-SCLC and discuss recent clinical evidence on B7-H3 ADCs presented at WCLC and ESMO 2025. Par...

Faculty: Luis Paz-Ares, MD, PhD Faculty: Lauren A. Byers, MD This online CME program will provide the latest clinical updates on B7-H3–directed antibody-drug conjugates (ADCs) in extensive-stage small cell lung cancer (ES-SCLC). Faculty experts will review the biological rationale for targeting B7-H3 in ES-SCLC and discuss recent clinical evidence on B7-H3 ADCs presented at WCLC and ESMO 2025. Par...

Faculty: Luis Paz-Ares, MD, PhD This online CME program will provide the latest clinical updates on B7-H3–directed antibody-drug conjugates (ADCs) in extensive-stage small cell lung cancer (ES-SCLC). Faculty experts will review the biological rationale for targeting B7-H3 in ES-SCLC and discuss recent clinical evidence on B7-H3 ADCs presented at WCLC and ESMO 2025. Participants will gain practical...

Faculty: Luis Paz-Ares, MD, PhD Faculty: Lauren A. Byers, MD This online CME program will provide the latest clinical updates on B7-H3–directed antibody-drug conjugates (ADCs) in extensive-stage small cell lung cancer (ES-SCLC). Faculty experts will review the biological rationale for targeting B7-H3 in ES-SCLC and discuss recent clinical evidence on B7-H3 ADCs presented at WCLC and ESMO 2025. Par...

Faculty: Luis Paz-Ares, MD, PhD Faculty: Lauren A. Byers, MD This online CME program will provide the latest clinical updates on B7-H3–directed antibody-drug conjugates (ADCs) in extensive-stage small cell lung cancer (ES-SCLC). Faculty experts will review the biological rationale for targeting B7-H3 in ES-SCLC and discuss recent clinical evidence on B7-H3 ADCs presented at WCLC and ESMO 2025. Par...

Faculty: Lauren A. Byers, MD This online CME program will provide the latest clinical updates on B7-H3–directed antibody-drug conjugates (ADCs) in extensive-stage small cell lung cancer (ES-SCLC). Faculty experts will review the biological rationale for targeting B7-H3 in ES-SCLC and discuss recent clinical evidence on B7-H3 ADCs presented at WCLC and ESMO 2025. Participants will gain practical in...

Host: Joseph F. Goldberg, MD Can you recognize the symptoms of major depressive disorder? Do you know when to augment and when to switch therapies? Join our experts for these answers and learn about novel treatments on the horizon. Don’t miss this opportunity to enhance your clinical practice and positively impact the lives of your patients.

Host: Patrick J. McCann, MD Faculty: Rajeev Mohan, MD Improving the overall quality of life for patients with heart failure with reduced ejection fraction, or HFrEF, is a key component of their care. But many patients may fail to reach symptom relief or experience improved functional status, even when receiving optimized pharmacologic guideline-directed medical therapy (GDMT). Medical devices like...